AUS
NZ
UK
CA
USA
IND
Highlights
- Noxopharm’s Sofra™ tech validated through BioRay testing
- Promising inflammation-fighting results from oligonucleotide platform
- Collaboration boosts Sofra’s potential as versatile ASX300 biotech innovation
Noxopharm Limited (ASX:NOX), a clinical-stage biotechnology company listed on the ASX300, has taken a significant step forward in its international collaboration efforts through a key partnership with China-based BioRay Pharmaceutical. This new alliance, formalized under a Material Transfer Agreement (MTA), is focused on testing and expanding the capabilities of Noxopharm’s proprietary Sofra™ platform.
Independent Study Confirms Anti-Inflammatory Strength
BioRay’s research efforts have yielded encouraging results. The study tested Sofra™ oligonucleotides and found them to exhibit targeted anti-inflammatory effects when conjugated with BioRay’s own antibodies. The outcomes demonstrated a measurable enhancement in inflammation marker reduction, offering external validation for the efficacy and scientific foundation of the Sofra™ technology.
This independent assessment provides not only a significant confidence boost for the platform but also highlights the increasing relevance of Noxopharm’s innovation in broader therapeutic applications, particularly those related to inflammation and immune regulation.
Global Collaboration Strengthens Growth Trajectory
Dr Gang Chen, Head of R&D at BioRay, shared enthusiasm about the results, emphasizing the synergy between the two organizations and the potential for shared innovation. Dr Gisela Mautner, CEO of Noxopharm, echoed this sentiment, underscoring the value of having BioRay—an international player—invest time and resources in verifying the potential of Sofra™.
With several MTAs already underway globally, Noxopharm is expanding its global footprint by partnering with pharmaceutical and biotech companies to apply Sofra™ across a range of therapeutic areas.
Innovation Aligned with ASX Dividend Stocks and ASX300 Themes
As part of the ASX300 index, Noxopharm's focus on robust research, intellectual property, and global collaborations places it among promising biotech innovators with potential appeal to long-term investors seeking strategic exposure to the healthcare sector. It also contributes to the growing list of biotechnology firms shaping future developments in the broader landscape of ASX dividend stocks, as more research-driven companies aim to reach commercial viability.
